Donovan Joanne M. 4
4 · Edgewise Therapeutics, Inc. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
Edgewise (EWTX) CMO Joanne Donovan Sells Shares
What Happened
Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (EWTX), sold a total of 16,358 shares in open-market transactions on March 27, 2026. The filing reports an average price of $30.98 per share (sales executed at prices in the range $30.49–$31.68), generating aggregate proceeds of approximately $506,734. These were outright sales (not purchases or option exercises).
Key Details
- Transaction date: March 27, 2026; Form 4 filed March 30, 2026 (filed within the standard reporting window).
- Shares sold: 9,623 shares and 6,735 shares (total 16,358).
- Price(s): average $30.98; actual transaction prices ranged from $30.49 to $31.68.
- Proceeds: about $298,099 and $208,635 (total ≈ $506,734).
- Shares owned after the transaction: not specified in the provided filing.
- Notable footnotes: sales involved shares originally acquired through the Edgewise 2021 Employee Stock Purchase Plan on multiple purchase dates (May/Nov 2022, May/Nov 2023, May/Nov 2024); filing notes one lot includes 594 shares purchased Nov 17, 2025. The $30.98 figure is an average price; the reporting person can provide per-price allocations on request.
Context
These were routine open-market sales of ESPP-acquired shares by a company executive. Sales do not necessarily indicate a change in company outlook; purchases are generally considered a stronger signal of insider confidence. This transaction was reported on a timely Form 4.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-03-27$30.98/sh−9,623$298,099→ 16,332 total - Sale
Common Stock
[F2]2026-03-27$30.98/sh−6,735$208,635→ 9,597 total
Footnotes (3)
- [F1]The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares).
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.